Crestone, Inc. is a drug discovery and development company focused on developing novel treatments

for serious bacterial infections. The company currently has two advanced pre-clinical programs that

address areas of significant and growing unmet medical need, both with novel mechanism of action agents.

1. Novel antibiotic for Clostridium difficile infections. CRS3123 (formerly know as REP3123) is in development

for the treatment of C. difficile infection (CDI). This disease occurs when toxin-producing bacteria colonize the 

gastrointestinal tract, and is associated with significant morbidity and mortality. Due to the development of hyper-

virulent drug-resistant strains, incidence has more than doubled in the last decade. We believe that CRS3123 will

be superior to current therapies, which have significant shortcomings. Phase 1 clinical studies for CRS3123 are

being conducted with the NIAID Division of Microbiology and Infectious Disease (DMID). IND filing is expected in 4Q11.

 

2. Novel oral agents for Gram-positive infections. Crestone is optimizing a novel class of DNA replication

inhibitors with Gram-positive antibacterial activity. This promising chemical series is currently in advanced

lead optimization, funded by an SBIR grant from NIAID. These molecules selectively inhibit an essential

component of the replicative DNA polymerase complex and are potent, orally available, and effective against

all clinically-relevant Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA),

vancomycin-resistant enterococci (VRE), penicillin-resistant Streptococcus pneumoniae (PRSP) and Bacillus

anthracis. We anticipate development of a drug similar to Zyvox in spectrum, but with key advantages such as

bactericidal activity and improved safety.